Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform trial of long-acting antibodies in moderate to severe active ulcerative colitis
MOH_2025-11-10_015449Phase 2Not yet recruiting
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SPY001, SPY002 and SPY003 in autoimmune colitis (10 arms), sponsored by Spyre Therapeutics, Inc. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
SPY001SPY002SPY003
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2025-11-10_015449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-10_015449.